By Colin Kellaher
Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer.
Bristol Myers on Friday said the approval covers the combination for the first-line treatment of adults with unresectable or advanced hepatocellular carcinoma.
Liver cancer is the third most frequent cause of cancer death worldwide, and hepatocellular carcinoma is the most common type of liver cancer, accounting for 90% of global cases, the Princeton, N.J., biopharmaceutical company said.
The Opdivo/Yervoy combination is already approved in several cancer indications worldwide. The U.S. Food and Drug Administration is reviewing the combination as a potential first-line treatment option for adults with unresectable hepatocellular carcinoma, with a target action date of April 21.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 07, 2025 07:12 ET (12:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.